Abstract
AIDS has claimed the lives of 25 million people worldwide, an additional 40 million people are HIV-infected and new cases are being diagnosed every year. Despite the fact that HAART has moved AIDS from the category of terminal diseases to that of treatable chronic illnesses, its long-term therapeutic success may be compromised by the development of resistance to the currently used drugs. Despite the availability of RT, PR and fusion inhibitors, the development of further drugs such as inhibitors that target the third enzyme IN is essential for the clinical management of HIV-infected patients. The absence of cellular homolgues to IN and the unique nature of the reactions catalyzed by IN, make it an ideal target for drug design. Considerable progress towards designing HIV-1 IN inhibitors has been made over the last years and several lead compounds have been identified, synthesized and clinically studied. This review focuses on the existing knowledge of the biology of HIV-1 IN with emphasis on the mechanism of integration, structure and function and the technologies for measuring IN activity. This is followed by the current trends on designing HIV-1 IN inhibitors with the aid of molecular informatics and a review on the main classes of HIV-1 IN inhibitors reported this far with special emphasis on the clinical candidates.
Keywords: HIV-1 integrase, computer-aided drug design, inhibitors
Current HIV Research
Title: HIV-1 Integrase: From Biology to Chemotherapeutics
Volume: 5 Issue: 4
Author(s): Eriketi Zeinalipour-Loizidou, Christos Nicolaou, Athanasios Nicolaides and Leondios G. Kostrikis
Affiliation:
Keywords: HIV-1 integrase, computer-aided drug design, inhibitors
Abstract: AIDS has claimed the lives of 25 million people worldwide, an additional 40 million people are HIV-infected and new cases are being diagnosed every year. Despite the fact that HAART has moved AIDS from the category of terminal diseases to that of treatable chronic illnesses, its long-term therapeutic success may be compromised by the development of resistance to the currently used drugs. Despite the availability of RT, PR and fusion inhibitors, the development of further drugs such as inhibitors that target the third enzyme IN is essential for the clinical management of HIV-infected patients. The absence of cellular homolgues to IN and the unique nature of the reactions catalyzed by IN, make it an ideal target for drug design. Considerable progress towards designing HIV-1 IN inhibitors has been made over the last years and several lead compounds have been identified, synthesized and clinically studied. This review focuses on the existing knowledge of the biology of HIV-1 IN with emphasis on the mechanism of integration, structure and function and the technologies for measuring IN activity. This is followed by the current trends on designing HIV-1 IN inhibitors with the aid of molecular informatics and a review on the main classes of HIV-1 IN inhibitors reported this far with special emphasis on the clinical candidates.
Export Options
About this article
Cite this article as:
Eriketi Zeinalipour-Loizidou , Christos Nicolaou , Athanasios Nicolaides and Leondios G. Kostrikis , HIV-1 Integrase: From Biology to Chemotherapeutics, Current HIV Research 2007; 5 (4) . https://dx.doi.org/10.2174/157016207781023965
DOI https://dx.doi.org/10.2174/157016207781023965 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fusions Involving PAX and FOX Genes in the Molecular Pathogenesis of Alveolar Rhabdomyosarcoma: Recent Advances
Current Molecular Medicine Thermosensitive Polymeric Hydrogels As Drug Delivery Systems
Current Medicinal Chemistry Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets CCR5 as a Potential Target in Cancer Therapy: Inhibition or Stimulation?
Anti-Cancer Agents in Medicinal Chemistry Targeting Apoptotic Pathways in Myocardial Infarction: Attenuated by Phytochemicals
Cardiovascular & Hematological Agents in Medicinal Chemistry Using Insights into Pim1 Structure to Design New Anticancer Drugs
Current Pharmaceutical Design Inhibition of Cdc42-Interacting Protein 4 (CIP4) Impairs Osteosarcoma Tumor Progression
Current Cancer Drug Targets Overview of the Formulations and Analogs in the Taxanes' Story
Current Medicinal Chemistry Optimizing Gene Silencing Strategies for Pancreatic Cancer
Current Cancer Therapy Reviews Global Expression Studies of Schizophrenic Brain: A Meta-Analysis Study Linking Neurological Immune System with Psychological Disorders
CNS & Neurological Disorders - Drug Targets Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets Population Diversity and its Relationship with Infectious and Tumor Diseases
Current Immunology Reviews (Discontinued) Recent Applications of RNAi in Mammalian Systems
Current Pharmaceutical Biotechnology Glucan Particles Loaded with Fluorinated Emulsions: A Sensitivity Improvement for the Visualization of Phagocytic Cells by <sup>19</sup>F-MRI
Current Molecular Imaging (Discontinued) Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Passive and Active Tumour Targeting with Nanocarriers
Current Drug Discovery Technologies The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations
Current Cancer Drug Targets T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry